The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

Abstract Background Concomitant high‐dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic c...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte W. Duinkerken, Sabrina Chiodo, Katrina Hueniken, Michael Hauptmann, Katarzyna Jóźwiak, Dangxiao Cheng, Andrew Hope, Geoffrey Liu, Charlotte L. Zuur
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Cancer Medicine
Subjects:
cisplatin
head and neck squamous cell carcinoma
hearing loss
MATE1
SNP
Online Access:https://doi.org/10.1002/cam4.7465
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.7465

Similar Items